Valderrama 1992.

Methods	Randomised clinical trial
Participants	Country: Spain Number randomised: 105 Postrandomisation dropouts: 5 (4.8%) Revised sample size: 100 Average age: 57 years Women: 53 (53%) Acute interstitial oedematous pancreatitis: not stated Necrotising pancreatitis: not stated Mild pancreatitis: not stated Moderate pancreatitis: not stated Severe pancreatitis: not stated Persistent organ failure: not stated Infected pancreatitis: not stated Inclusion criteria: people with acute pancreatitis
Interventions	Group 1: gabexate mesilate (n = 51), 12 mg/kg/day continuous IV for 4‐12 days based on disappearance of abdominal pain or requirement for surgery Group 2: placebo (n = 49)
Outcomes	Mortality, serious adverse events, adverse events, sepsis Follow‐up: not stated (probably until discharge)
Notes	Reasons for postrandomisation dropouts: protocol violations
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "computer generated"
Allocation concealment (selection bias)	Low risk	Quote: "consecutively numbered boxes containing FOY or placebo"
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "double blind"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "double blind"
Incomplete outcome data (attrition bias) All outcomes	High risk	Comment: there were postrandomisation dropouts.
Selective reporting (reporting bias)	Low risk	Comment: mortality and adverse events were reported.
For profit‐bias	High risk	Quote: "[t]he authors thank Laboratorio Dr Esteve SA for supplies of gabexate mesylate (FOY)".
Other bias	Low risk	Comment: no other risk of bias